Schonfeld Strategic Advisors LLC Black Diamond Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.77 - $3.03 $120,221 - $205,803	-67,922 Reduced 45.55%	81,178 $228,000
Q3 2023 Nov 14, 2023	BUY	$2.87 - $4.99 $427,917 - $744,009	149,100 New	149,100 $427,000
Q3 2022 Nov 14, 2022	SELL	$1.68 - $4.01 $1,344 - $3,208	-800 Reduced 5.41%	14,000 $23,000
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.63 $7,650 - $18,513	-5,100 Reduced 25.63%	14,800 $37,000
Q1 2022 May 16, 2022	BUY	$2.66 - $5.61 $13,832 - $29,172	5,200 Added 35.37%	19,900 $55,000
Q4 2021 Feb 14, 2022	SELL	$5.18 - $8.48 $1,036 - $1,696	-200 Reduced 1.34%	14,700 $78,000
Q3 2021 Nov 16, 2021	SELL	$8.46 - $12.42 $115,056 - $168,912	-13,600 Reduced 47.72%	14,900 $126,000
Q2 2021 Aug 16, 2021	BUY	$12.19 - $28.17 $347,415 - $802,845	28,500 New	28,500 $347,000
Q1 2021 May 17, 2021	SELL	$22.23 - $34.75 $740,547 - $1.16 Million	-33,313 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.47 - $35.0 $743,027 - $882,455	25,213 Added 311.27%	33,313 $1.07 Million
Q3 2020 Nov 19, 2020	BUY	$26.17 - $43.07 $211,977 - $348,867	8,100 New	8,100 $244,000

117

48.8M

1.84M

1.93M

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $79.6M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.